FIREFLY NEUROSCIENCE, INC. (AIFF)
Firefly Neuroscience is an AI-powered brain analytics firm that reads electrical signals from the brain to diagnose neurological and psychiatric conditions and help pharmaceutical companies test new drugs faster. The company uses proprietary EEG-based technology called BNA™ (Brain Network Analysis), which has FDA clearance, to turn raw electroencephalogram data into clinical signals—identifying patterns linked to dementia, anxiety, concussions, ADHD, and other brain disorders. Rather than waiting weeks or months to see whether a treatment works, BNA can flag changes in brain electrical activity within the diagnostic window.
The business model runs on two separate tracks. Clinically, Firefly works with neurologists and psychiatrists across the United States, positioning BNA as a diagnostic aid to help doctors move away from guesswork and trial-and-error medication adjustments. Pharmaceutically, the company partners with drug developers who use BNA as a biomarker during clinical trials—a shorter, cheaper way to measure whether a candidate compound is actually affecting brain function. This dual revenue stream targets both healthcare provider budgets and the pharma industry, where failed drug candidates waste billions in development costs.
Firefly listed on Nasdaq in November 2024 under the ticker AIFF. In May 2025, the company acquired Evoke Neuroscience, expanding its technology portfolio and moving toward building a machine learning system trained on large-scale neural data—what management calls a “proprietary foundation model of the human brain.”
The fundamental bet is straightforward: brain electrical recordings contain digital patterns that artificial intelligence can learn to interpret faster and more reliably than clinical eye. The company licenses software and sells biomarker services. Growth depends on convincing healthcare systems and drug makers that the technology improves patient outcomes, reduces development timelines, and justifies the cost of adoption through insurance reimbursement and pharma partnerships.
Main products and service lines:
- BNA brain analytics software (clinical diagnostic use)
- BNA research and biomarker services (pharmaceutical trials)
- Evoke Neuroscience platform (acquired 2025)
- FDA-cleared EEG analysis tools